The Food and Drug Administration reversed course and agreed to begin a review of Moderna’s application to sell a new seasonal flu shot after the vaccine maker agreed to conduct additional testing in ...
Add Yahoo as a preferred source to see more of our stories on Google. Moderna said the FDA's refusal was inconsistent with previous feedback from the agency. - Graham Hughes/Bloomberg/Getty Images The ...
All nine members of the committee unanimously voted to recommend Moderna's new mRNA influenza vaccine for adults 50 and over.
The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for approval of its new flu vaccine, which is its first using mRNA technology ...
Moderna Inc.’s shares plunged after U.S. regulators refused to review its novel mRNA flu vaccine, dealing a major blow to the company as it seeks more products beyond its COVID shot. The U.S. Food and ...
The Food and Drug Administration reversed its decision on Moderna’s flu vaccine and has agreed to review it for possible approval. Just last week, Moderna announced that the agency had rejected its ...
Morning Overview on MSN
A Moderna mRNA flu shot won a unanimous FDA panel nod for older adults
Older adults who face the highest rates of flu hospitalization moved one step closer to a new vaccine option on June 18, 2026, when a federal advisory panel unanimously backed Moderna’s mRNA-based ...
The Food and Drug Administration reversed course on Wednesday and agreed to formally review Moderna’s new flu vaccine that uses mRNA technology, the company announced in a news release. Earlier this ...
Feb. 18 (UPI) --Moderna's mRNA-1010 flu vaccine for older adults could be made available by the end of 2026, the pharmaceutical company announced Wednesday. Officials at the Food and Drug ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The compromise clears a path for ...
Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu ...
The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date. In a regulatory turnaround, the FDA will now review Moderna’s seasonal mRNA flu vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results